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Abstract 
Background: A Tat Oyi vaccine preparation was administered with informed consent to 48 long‑term HIV‑1 infected 
volunteers whose viral loads had been suppressed by antiretroviral therapy (cART). These volunteers were rand‑
omized in double‑blind method into four groups (n = 12) that were injected intradermally with 0, 11, 33, or 99 µg of 
synthetic Tat Oyi proteins in buffer without adjuvant at times designated by month 0 (M0), M1 and M2, respectively. 
The volunteers then underwent a structured treatment interruption between M5 and M7.
Results: The primary outcomes of this phase I/IIa clinical trial were the safety and lowering the extent of HIV RNA 
rebound after cART interruption. Only one undesirable event possibly due to vaccination was observed. The 33 µg 
dose was most effective at lowering the extent of HIV RNA and DNA rebound (Mann and Whitney test, p = 0.07 and 
p = 0.001). Immune responses against Tat were increased at M5 and this correlated with a low HIV RNA rebound at 
M6 (p = 0.01).
Conclusion: This study suggests in vivo that extracellular Tat activates and protects HIV infected cells. The Tat Oyi vac‑
cine in association with cART may provide an efficient means of controlling the HIV‑infected cell reservoir.
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Background
The quest for an efficient vaccine against HIV has been 
a major issue since the initial cloning and identification 
of HIV-1 as the causative agent of AIDS [1, 2]. Although 
there is consensus that HIV eradication will require 
elimination of HIV infected cells that are mainly CD4 T 
lymphocytes (CD4), no cART and/or vaccine approaches 
have been able to reduce significantly the level of HIV 
infected cells in peripheral blood until now [3]. Different 
reasons to explain this lack of efficacy include the pos-
sibility that HIV variability is too high for the immune 
system [4]. The development of cART from 1996 showed 
that even with a low HIV-1 variability, the immune sys-
tem is still unable to eradicate HIV infected cells [5]. The 
reservoir of HIV infected cells in the peripheral blood 
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is made of cells at the latent state, which is remarkably 
stable since its eradication even with successful cART 
would require at least 70 years [6]. Why cytotoxic or CD8 
T Lymphocytes (CTL) can not eliminate HIV infected 
cells remains controversial and it has been proposed that 
the central nervous system (CNS) could be a sanctuary 
(CTL have no access to CNS due to the blood–brain bar-
rier) that would refresh peripheral blood with activated 
HIV infected cells [7]. However, the development of HIV 
DNA measurements points out CNS as a minor reservoir, 
while guts and rectal tissues called GALT and RALT are 
the major tissue reservoirs and CTL have access to theses 
tissues [8, 9]. Only GALT and RALT have HIV sequences 
compatible with the refreshment of peripheral blood 
with activated HIV infected cells [8]. Even patients with 
undetectable viraemia show evidence of ongoing viral 
replication in these tissue reservoirs and there is equilib-
rium with the peripheral blood compartment [10]. It was 
shown recently that HIV infected cells become rapidly 
resistant to CTL following HIV infection [3]. It could be 
possible that the capacity for HIV infected cells to survive 
in an environment containing CTL is due to the secretion 
from HIV infected cells of a HIV protein called Tat [11]. 
The presence of extracellular Tat in peripheral blood has 
been demonstrated in different clinical studies showing 
the presence of antibodies against Tat [11]. Extracellular 
Tat goes on to be secreted under ART and might protect 
HIV infected cells from CTL dues to its capacity to cross 
CTL membranes to trigger apoptosis [11]. Furthermore, 
extra cellular Tat might activate latent HIV infected 
cells and explain the rapid HIV rebound when cART is 
stopped [11]. However, there is a paucity of informa-
tion on the role that extracellular Tat plays in infected 
subjects.
A single individual termed the “Berlin patient”, who 
was infected by HIV in 1995 is acknowledged to have 
been cured of HIV after having received a hematopoi-
etic stem cell transplantation in 2007 from a compatible 
donor possessing the delta 32 mutation in CCR5 [12]. 
HIV DNA was no longer detectable in his peripheral 
blood in 2009 [13]. The complete eradication of HIV in 
this patient was demonstrated in 2012 by a retro serocon-
version that is characterized by a significant decrease of 
antibodies against HIV [13]. A similar retro seroconver-
sion was reported for the child termed the “Mississippi 
baby” at age of three [14]. HIV-1 antibodies were not 
detected in the child at 24, 26, and 28 months of age, but 
were found when she was 4  years old in 2014 due to a 
viral rebound [15]. Retro seroconversion has never been 
observed in patients receiving cART with no detectable 
viraemia and is therefore considered to be a marker for 
the elimination of HIV infected cell [11, 13]. In contrast, 
low-level viraemia that is below the limit of detection of 
viral RNA can be enough to sustain a high level of anti-
bodies against HIV in spite of efficient ART [8].
Retro seroconversions were also observed after a sur-
vey of 2 years in 23 of 25 women who were seropositive 
in 1986 in Gabon but at the time this was interpreted as 
due to mutations in the HIV envelope protein [16]. A 
HIV strain termed HIV-1 Oyi was cloned from one of 
these women while she was still seropositive [16]. It was 
later shown that HIV Oyi had envelope proteins similar 
to other HIV strains and a correlation was established 
between the retro seroconvertion of these 23 women 
and the capacity for Tat Oyi to have immune proper-
ties never observed in other Tat variants [17]. This led 
to the testing of a Tat Oyi vaccine on rhesus macaques 
that were challenged by mucosal inoculation with a het-
erologous recombinant SHIV. The results showed that 
SHIV infected CD4 cells were no longer detectable in 
the peripheral blood 2 months after SHIV challenge in all 
macaques vaccinated with Tat Oyi and one of these ani-
mals retro seroconverted [18]. The efficacy of Tat Oyi was 
recently confirmed in another heterologous SHIV chal-
lenge [19]. It was also possible to identify a highly con-
served surface on Tat variants and Tat Oyi has specific 
mutations that transform this highly conserved surface 
in a 3D épitope [20]. Tat Oyi can generate neutralizing 
antibodies against Tat variants whatever their mutations 
establishing a rational for testing Tat Oyi as active princi-
ple of a therapeutic vaccine in human trials [11].
This study describes the first clinical trial with Tat Oyi 
in a phase I/II double blinded and randomized controlled 
clinical trial. The primary outcome of phase I was the 
absence of serious adverse events (SAE) due to vaccina-
tion. The primary outcome for phase II was the capacity 
to control HIV RNA rebound in a vaccine group follow-
ing treatment interruption. The secondary outcome for 
phase I and phase II was a specific immune response 
against Tat related to the vaccine and characterized by 
amplification and/or cross recognition of six Tat vari-
ants (including Tat Oyi) that are representative of the five 
main HIV-1 subtypes [11].
Results
Study design and eligibility criteria
The hypothesis was that neutralizing antibodies against 
Tat induced by this vaccine may help CTL to elimi-
nate HIV infected cells. The Tat Oyi vaccine rationale 
is not to develop a Tat specific CTL response since HIV 
infected cells have GP120 at their surfaces and not Tat. 
Free extracellular Tat may constitute a screen that pro-
tects HIV infected cells from CTL. Neutralizing antibod-
ies against Tat may destroy this screen. We proposed to 
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test the Tat Oyi vaccine to HIV-1 infected volunteers 
who were virologically suppressed for at least 1  year 
while on ART. Three double blinded intradermal injec-
tions (500  µL) at Month 0 (M0), M1 and M2 of a solu-
tion having respectively 0, 11, 33 or 99 µg in four groups 
of volunteers. The vaccine was composed essentially of 
a synthetic Tat Oyi in 100 mM Phosphate buffer pH 4.5 
and 9  g/L NaCl. Three intradermal injections were car-
ried out in each group and the only difference with the 
placebo group was the absence of Tat Oyi. No adjuvant 
or other compounds were added. Volunteers agreed to 
stop cART for 2 months between M5 and M7, but cART 
could be resumed if a volunteer was >100 copies/mL HIV 
RNA at M6. Observance of cART and cART interrup-
tion between M5 and M7 were monitored by detection 
of antiretroviral levels in blood samples over the course 
of the study.
Volunteers had been recruited from among long term 
suppressed HIV infected patients who did not experience 
cART in early infection. cART interruption of 2 months 
is considered to be safe for these HIV infected patients 
with a CD4 counts >350 cells/mm3 and in whom a limited 
decrease of about 65 CD4 cells/mm3 has been observed 
[21, 22]. HIV RNA rebound, following cART interruption 
for these patients is characterized by the appearance of 
detectable HIV RNA at day 15 that increases until stabi-
lization (up to 30 days) with a mean 10,000 (log 4) HIV 
RNA copies/mL [21]. This dynamic can be different for 
HIV patients who received cART during primary infec-
tion [15, 23, 24], perhaps because early initiation of cART 
may reduce the size of the HIV DNA reservoir [<1.5 log 
HIV DNA copies per 106 peripheral blood mononuclear 
cells (PBMC)] potentially influencing HIV RNA rebound 
when cART is interrupted [23]. Levels of HIV DNA in 
peripheral blood of patients receiving cART (without 
early initiation) since <10  years appear to be constant 
with a median of 1.9 log HIV DNA copies per 106 PBMC 
and a mean difference of 0.2  log copies per 10  years of 
effective cART [25, 26].
Base line and safety
Fifty-one volunteers were initially included and filled a 
written informed consent but only 46 followed the pro-
tocol to the end. The mean and median age was 46 years 
old, 27 % (n = 13) were women, they had no co infec-
tion with hepatitis viruses, they have CD4 >350  cells/
mm3 and were never under 200 CD4 cells/mm3 since 
12  months (see Table  1 for base line and EVATAT in 
clinicaltrial.gov for the complete inclusion and exclu-
sion criteria). Only one SAE (a facial neuralgia for 
1  week) that occurred 11  months after vaccination 
with three 11 µg vaccine doses was considered as pos-
sibly related to vaccination (Table  2). The participant 
flow diagram shows that four other patients had a Seri-
ous SAE between first assessment in March 2013 and 
when the last patient left the trial at M12 in December 
2014 (Fig. 1). One of these four SAE occurred between 
the time of assessment and the first vaccination (M0) 
and another SAE was a chirurgical intervention pro-
grammed before vaccination (Table  2). The two other 
SAE were tuberculosis and a diarrhea related to ART 
and it is not possible to establish a relationship with 
vaccination.  




 Mean 46.4 (±9.7)
 Median (Q1–Q3) 47.0 [42.0–51.5]
Sexe n (%) woman 13 (27 %)
HIV infection diagnosis (years)
 Mean 12.4 (±7.9)
 Median (Q1–Q3) 12.0 [4.8–20.3]
Years since HIV RNA <40 copies/mL
 Mean 6.0 (±4.3)
 Median (Q1–Q3) 4.6 [2.1–9.7]
ART
 Nucleoside base 1 (2.1 %)
 Non nucleosidic 28 (58.3 %)
 Protease 15 (31.3 %)
 Integrase 4 (8.3 %)
HIV DNA (copies/106 PBMC)
 Mean 86.7 (±117.2)
 Median (Q1–Q3) 49.5 [1.0–111.0]
Log HIV DNA
 Mean 1.7 (±0.5)
 Median (Q1–Q3) 1.7 [0.0–2.1]
CD4 (cells per µL)
 Mean 692.4 (±259.6)
 Median 666.0 [515.0–791.5]
CD8 (cells per µL)
 Mean 688.3 (±309.8)
 Median (Q1–Q3) 654.0 [475.0–753.0]
CD4/CD8
 Mean 1.1 (±0.4)
 Median (Q1–Q3) 1.1 [0.8–1.4]
Nadir (CD4 <350 cells per µL) (years)
 Mean 5.8 (±4.9)
 Median (Q1–Q3) 4.4 [2.0–8.3]
Nadir CD4 (cells per µL)
 Mean 336.3 (±114.0)
 Median (Q1–Q3) 312.0 [265.0–390.0]
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HIV RNA
The 46 volunteers did not have detectable HIV RNA for 
at least 1  year before to stop cART at M5 (Fig.  2). Ten 
volunteers did not resume cART at M6. The primary 
outcome of the phase IIa study was reached with 33 µg 
showing a lowering of the extent of HIV RNA rebound 
median from 4.1 to 2.6 log copies/mL (Fig. 2) with eight 
volunteers (66 %) being <3.5 log copies/mL (Fig. 3). Four 
volunteers (33 %) in the 33 µg group were able to main-
tain their viremia <2  log copies/mL after cessation of 
cART (Fig. 3) and did not resume their treatment at M6. 
In the three other groups (including the placebo group) 
two volunteers did not resume cART at M6. We observe 
in Table 3 that the analysis of the four groups confirmed 
that 33  µg gave the best control of RNA rebounds with 
the lowest median. A one sided Mann and Whitney test 
that compared the placebo and the 33 µg group showed 
that differences between the two were borderline sig-
nificant (p =  0.07), while the two other vaccine groups 
yielded none significant differences (p > 0.1).
CD4 and CD8 cell
The 11  µg group seemed to yield a significant increase 
(variation >65 CD4 cells/mm3) from 554 (total range or 
TR was 418–1067) to 636 (TR 502–1124) CD4 cells/mm3 
Table 2 Serious adverse events (SAE) (phase I primary end 
point)
a Time is expressed in months (M) after the first injection or in days (D) before 
the first injection
Volunteers Groups (µg) Events Timea Due to vaccine
No 2 11 Facial neuralgia M11 Possible
No 24 99 Diarrhea M3 Doubtful
No 36 99 Tuberculosis M3 Doubtful
No 41 33 Hernia hiatus repair M9 Not possible
No 47 33 Haemorrhoids D‑7 Not possible
Assessed for eligibility (n= 51)
Excluded (n=3)
¨ Detectable viremia (n=1) 
¨ Declined to participate (n=2)
Analysed  (n= 12)
Excluded from analysis (n=0)
Lost to follow-up (n= 0)
Discontinued intervention (n= 0)
PLACEBO (Phos. Buffer 100 mM pH 4.5, 
NaCl 9g/l)
Allocated to intervention (n= 12)
¨ Received allocated intervention (n= 12)
¨ Did not receive allocated intervention (n=0)
Lost to follow up (n=0)
Tuberculosis (n=1) (99 µg)
Declined to participate (n=1) (99 µg)
Discontinued intervention (n=2)
Tat Oyi (11, 33 or 99 µg with Phos Buffer 
100 mM pH 4.5, NaCl 9g/l)
Allocated to intervention (3x12 n=36)
Received allocated intervention (n= 36)
Did not receive allo cated intervention (n= 0)
Analysed  (n= 34)
Excluded from analysis due to discontinuated
Intervention (n=2) related to no treatment 
interruption between M5 and M7
Randomized (n= 48)
Fig. 1 EVATAT flow diagram. This flow diagram was constructed according to CONSORT recommendation [41]
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at M5 (Fig. 4a). Mann and Whitney test (M5 vs. M0) con-
firmed that 11 µg had a significant increase (p = 0.001) 
compared to 33  µg (p  =  0.22) and 99  µg (p  =  0.92) in 
a Mann and Whitney test. After treatment interrup-
tion, the four groups had a similar decrease from 671 
(TR 533–773) to 519 (TR 453–677) CD4 cells/mm3 for 
n = 46. No effect of the vaccine was detectable on CD4 
levels following treatment interruption. However, the 
33  µg group at M12 had an increase compared to M0 
from 706 (TR 542–783) to 784 (TR 554–837) CD4 cells/
mm3, while the placebo group had a decrease between 
M0 and M12 going from 615 (TR 436–781) to 476 (TR 
436–677) CD4 cells/mm3 (Fig.  4a). Higher variability 
was observed with CD8 levels, especially for the placebo 
group CD8 level with the 11 µg group being significantly 
higher at M5 (p = 0.004). The CD8 level with the 33 and 
99 µg groups appeared to be higher after treatment inter-
ruption (Fig. 4b). The median of the CD4/CD8 ratio was 
<1 for the 12 months of the study excepted at M6, where 
it was 1.25 with 33 µg and 0.96 with 99 µg, while it was 
0.75 with the placebo and 0.88 with 11 µg.
HIV DNA
Cell-associated total HIV DNA measured in this study 
can not be considered as a true measurement of HIV-
1-infected cells that persist in peripheral blood during 
cART, which are the source of rebound viremia upon 
























Fig. 2 Design of the study and HIV RNA Rebound. HIV‑1 infected 
volunteers (n = 46) were randomized into four groups having at 
month 0 (M0), M1 and M2 double blinded intradermal injections with 
respectively 0 (n = 12‑black square), 11 µg (n = 12‑black circle), 33 µg 
(n = 12‑white square) or 99 µg (n = 10‑white circle) of a synthetic pro‑
tein called Tat Oyi in a saline buffer without adjuvant. The volunteers 
stopped their antiviral treatment between M5 and M7. Volunteers 
had undetectable HIV RNA since at least 1 year before vaccination 
and treatment interruption. HIV RNA rebound is displayed as the 
median for each group on a logarithm scale. Four volunteers did 
not resume ART at M6 in the 33 µg group while only two volunteers 
resumed ART in the other groups. HIVRNA at M7 is depicted for vol‑




















0 11µg 33µg 99µg
Fig. 3 HIV RNA at M6 for each volunteer. The HIV RNA level (copies/
mL) is displayed on a logarithmic scale. For each group, the median is 
shown as a grey line
Table 3 Vaccine efficacy to  prevent HIV RNA rebound 
(phase II primary end point)
HIV RNA at M6 after cART interruption at M5
* p values were determined for each vaccine group versus placebo with a one 
sided Mann and Whitney test without adjustment. Undetectable viraemia (<40 
copies/ml) were replaced by 39 (1.6 log) copies/ml








12,921 20,706 442 9475
Total range 39–0.9 × 106 39–1.2 × 106 39–0.4 × 106 81–0.1 × 106
Log medians 4.1 4.3 2.6 4.0



































Fig. 4 Levels of CD4 and CD8 lymphocytes. a Median CD4 count for 
each group. b Median CD8 count for each group. Group 1 is depicted 
as a black square, group 2 as a black circle, group 3 as a white square 
and group 4 as a white circle
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both integrated HIV DNA in HIV infected cells and free 
HIV DNA resulting from HIV infected cells desegrega-
tion. The most significant decrease in HIV DNA was 
observed with the 99 µg group (n = 10) between M0 and 
M4 (Fig. 5). Median decreases from 1.8 (TR 1.3–2.5) to 
1.3 (TR 1.3–2.6) log copies HIV DNA/106 PBMC were 
observed in six volunteers having HIV DNA <20 copies at 
M4. However, an equivalent increase occurred between 
M4 and M5 (before treatment interruption) and contin-
ued after treatment interruption at M6. Furthermore, the 
difference between M0 and M4 with 99 µg is not signifi-
cant (p = 0.27). Only the 33 µg group did not show a HIV 
DNA rebound after treatment interruption at M6 with 
five volunteers having HIV DNA <20 copies. The absence 
of HIV DNA rebound is significant with a Mann and 
Whitney test (p  =  0.001) compared to 99  µg (p  =  0.1) 
and 11 µg (p = 0.49). The HIV DNA decrease with 33 µg 
was less spectacular but was prolonged from M0 to M12 
(Fig. 5). At M12, the 33 µg group has a median of 1.4 log 
copies/mL that is very close of the undetectable level, but 
this difference is not significant (p  >  0.1) compared to 
M0. Four volunteers with 33 µg and three volunteers with 
99 µg were still having HIV DNA <20 copies at M12. This 
result suggests that extracellular Tat probably protects 
latent HIV infected cells.
IgG anti Tat response
Immune responses against Tat were based on the capac-
ity to recognize and/or increase recognition of six dif-
ferent Tat variants representative of the five main HIV-1 
subtypes in a sandwich ELISA test [11]. Four categories 
were observed with recognition of none, recognition of 
one Tat variant (low responder), recognition of two Tat 
variants (moderate responder), and recognition of three 
to six Tat variants (high responder). Prior to vaccination, 
specific responses against Tat were mostly low (39  %) 
or non-existent (26  %) (Fig.  6). Only 17  % were high 
responder but this increased to 63 % (n = 29) at M5 after 
vaccination. Five volunteers who had no Tat response 
before vaccination never developed an immune response 
against Tat in spite of three injections of either 11  µg 
(n  =  2), 33  µg (n  =  2) and 99  µg (n  =  1). Vaccination 
in two volunteers had an immune response against Tat 
unchanged before and after vaccination, one who receive 
11 µg while the other received the 99 µg dose. Therefore, 
7/34 volunteers (20 %) did not respond to Tat Oyi injec-
tion. Four volunteers who where high responders prior to 
vaccination did not display responsiveness after injection 
of 33 µg (n = 1) and 99 µg (n = 3) of Tat Oyi. The high-
est increase in Tat immune response at M5 was seen with 
the 33  µg dose since eight patients (67  %) have a high 
immune response against Tat (Fig.  6d). To try to deter-
mine the role of anti Tat immune responsiveness in HIV 
RNA rebound, we compared at M5 the high respond-
ers (n =  28) with the three other groups (n =  18). The 
high responders median was 3.3 while the median for the 
three other groups was 4.6 log copies/mL (p = 0.01). This 
finding suggests that the anti Tat immune response may 
prevent the ability of extracellular Tat to activate latently 
HIV infected cells.
Discussion
The only successful phase II vaccine clinical trial against 
HIV used a recombinant virus triggering envelope pro-
teins (RV144), and demonstrated an efficacy of about 
30  % at preventing HIV infection [27]. Two previous 
phase II clinical trials were performed with Tat fragments 
(TUTI-16) [28] or with recombinant Tat (ISST-02) [29]. 
Interestingly, in these two clinical trials as in this one, a 
dose of 30 µg of Tat yielded the best results [28, 29]. Three 
years after vaccination in the ISST-02 protocol, a signifi-
cant increase in CD4 cells and a HIV DNA decrease of 
0.2 log copies/106 PBMC occurred but there was no pla-
cebo group to determine if these results were related to 
the vaccine [30]. Another phase II clinical trial with the 
same vaccine (ISST-03) is ongoing in South Africa [30].
The Tat Oyi vaccine is entirely synthetic and no adju-
vant or compounds such as interleukins were added to 
amplify the immune response. The results presented 
1.5
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Fig. 5 HIV DNA in peripheral blood. HIV DNA medians for each 
group are shown from M0 to M12. Volunteers with undetectable HIV 
DNA (<20 copies/106 PBMC) were counted as having respectively 19 
copies, which is 1.3 log copies/ml (dashed line). The placebo group is 
depicted as a black square, the 11 µg group as a black circle, the 33 µg 
group as a white square and the 99 µg group as a white circle. Median 
decreases in HIVDNA levels were observed at doses of 99 µg (n = 10) 
from 1.8 (TR 1.3–2.5) to 1.3 (TR 1.3–2.6) log copies HIV DNA/106 PBMC 
between M0 and M4 and is due to six volunteers with HIV DNA cop‑
ies <20. The absence of HIVDNA rebound at M6 with the 33 µg group 
is highly significant in a Mann and Whitney test (p = 0.001). At M12, 
the 33 µg group has a median of 1.4 log copies/ml that is very close 
of the undetectable level. However, this difference is not significant 
(p > 0.1) compared to M0
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in this study are therefore due only to Tat Oyi, and the 
differences observed between the three different doses 
employed and the placebo are related only to the quan-
tity of Tat Oyi injected. HIV RNA rebound following 
treatment interruption was chosen as a primary out-
come to evaluate vaccine efficacy in phase II (M5 to 
M12). Tat Oyi is the first vaccine to demonstrate effi-
cacy in the context of cART interruption, even though 
21 other trials have tried and failed to show differences 
from the placebo group [31]. It is important to out-
line that lowering the extent of HIVRNA rebound to 
<0.5  log copies is considered as significant [31]. Since 
we have 8 volunteers <3.5  log copies/mL in the 33  µg 
group, it suggests an efficacy of 66  % for the Tat Oyi 
vaccine regarding the HIV RNA rebound. The immune 
response against Tat was monitored by ELISA test using 
Tat variants representative of the five main HIV-1 sub-
types [11]. Previously, we showed using this ELISA test 
that an immune response against Tat variants was pre-
sent for at least 50 % of HIV infected patients in African 
and European cohorts due to endogenous extracellu-
lar Tat [11]. Furthermore, we showed that this anti-Tat 
immune response could often be transient [11]. This 
study shows that anti-Tat immunity can help to control 
HIV RNA rebound and that the anti-Tat Oyi response 
may help to lower HIV DNA.
This study confirms in humans the important role of 
extracellular Tat in activating latent cells. Latency is a 
way for HIV, as other defective viruses, to maximize 
gene expression while avoiding global T cell activa-
tion that would involve the rapid elimination of HIV 
infected cells since activated T cells can survive for only 
a few days [4]. Different molecular mechanisms of HIV 
latency have been recently reviewed including Tat and 
other transcription factors such as NF-κB, the cyclin 
dependent kinases CDK13 and CDK11, and the posi-
tive transcription elongation factor b (P-TEFb) [32]. It 
is interesting that different strategies called “shock and 
kill” have been proposed to cure AIDS with agents 
that activate these proteins or release P-TEFb [32]. An 
anti-Tat compound such as Dihydro-cortistatin A can 
suppress HIV transcription but also inhibits HIV-1 
mediated neuro inflammation [33]. The blood–brain 
barrier appears to be damaged in HIV infected patients, 
and extracellular Tat may be involved in this process 
[33]. This damage may be due to CTLs that are present 
in the CNS in the mouse model [34]. This recent discov-
ery does not fit well with the role of sanctuary that the 
CNS is thought by some to play for HIV infected cells. 
The Tat Oyi vaccine may help to diminish HIV-associ-
ated neurocognitive disorders.
Conclusion
The intradermal administration of the Tat Oyi vaccine 
was safe and could attain the effects described without 
adjuvant. The lack of efficacy of the vaccine at a dose 
of 99  µg from M5 may be due to a collapse of the Tat 
immune response before M5. Tat Oyi is the first thera-































 D-15 M5  M12
Fig. 6 Evolution of the IgG anti Tat immune response in ELISA test. 
Data are shown before vaccination (D‑15), after vaccination at M5 
(just before ART interruption) and at M12 (5 months after ART was 
resumed). The volunteers were classified in four categories: The 
white bar corresponds to no recognition of Tat variants. The different 
shades of grey correspond to the capacity for volunteers to recognize 
one (low responder), two (moderate responder) or three to six (high 
responder) Tat variants. a Evolution of the Tat immune response for 
all volunteers (n = 46). b Evolution of the Tat immune response in the 
placebo group (n = 12). c Evolution of the Tat immune response in 
the 11 µg group (n = 12). d Evolution of the Tat immune response in 
the 33 µg group (n = 12). e Evolution of the Tat immune response in 
the 99 µg group (n = 10)
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to both HIV RNA and DNA in a phase II clinical trial. 
The Tat Oyi vaccine appears to reduce HIV DNA and 
potentially the numbers of HIV infected cells in periph-
eral blood. Preliminary results show that three volunteers 
who received 33 or 99 µg are still HIV DNA undetectable 
at M24. The Tat Oyi vaccine together with cART may 
provide a means of control of HIV infection.
Methods
Participants
The protocol was entitled: “Evaluation in seropositive 
patients of a synthetic vaccine targeting the HIV Tat pro-
tein” with the acronym: “EVATAT”. The protocol was reg-
istered in the European Clinical trial data base (EudraCT) 
with the ID number: 2012-000374-36. The protocol got a 
favorable advice from an ethic committee (CPP SudMed 
2) on November 9th, 2012 and an authorization from 
the French drug agency (ANSM) on January 14th, 2013 
and was registered in clinicaltrial.gov with the reference 
NCT01793818. A written informed consent was obtained 
from all participants. This was a monocentric clinical trial 
located in the University Hospital Center “la Conception” 
in Marseille (Provence). All the volunteers were French 
citizens living in different cities in Provence, the average 
age was 46  years old with the oldest being 64  years old 
and the youngest 32 years old. The main inclusion crite-
ria were: Age from 18 to 64 years old, on effective ART 
for at least 12  months with a viral load <40 copies/mL. 
The main exclusion criteria: Patients in HIV-1 primo 
infection, HIV-2 infected, having antibodies against 
HBV, HCV or HTLV-1 viruses, chronic active infections, 
immunosuppressive therapy, cancer, pregnancy and 
breastfeeding. Adverse events were monitored and clini-
cal examination performed at each visit, with blood sam-
pling for safety (general biochemistry and hematology). 
HIV RNA was analyzed by conventional methods with 
respectively a cut off of 40 copies per mL and HIV DNA 
HIV-1 DNA levels were measured by using the Generic 
HIV® assay (Biocentric, Bandol, Provence) with a cut off 
of 20 copies/million of PBMC. CD4+ and CD8+ T cell 
counts were analyzed by conventional methods.
Vaccine preparation
The active principle is a synthetic protein of 101 amino 
acid residues termed Tat Oyi [11]. Tat Oyi was synthe-
sized in the ETRAV laboratory (Faculty of Pharmacy, 
Marseille, Provence) in Fmoc solid phase synthesis with 
a synthesizer APPLIED 433A in one run as previously 
described [35]. Two clinical lots (Freeze dried 33 µg Tat 
Oyi and Phosphate buffer 100  mM pH 4.5 NaCl 9  g/L) 
were produced by the pharmaceutical company ELI-
APHARM at Sofia Antipolis (Provence). The two clinical 
lots were sterile and stable for 3 years at 4 °C. The vaccine 
was reconstituted by the CHU Conception hospital phar-
macy on the day of administration by mixing freeze dried 
Tat Oyi (0, 11, 33 or 99 µg) with the buffer.
Immune response against Tat
The antibody response against Tat was monitored with 
an ELISA test using Tat variants representative of the 
five main HIV-1 subtypes and Tat Oyi [11] in the ETRAV 
laboratory. For each volunteer, six blood samplings were 
carried out at M0, M2, M5, M7, M9 and M12 and sera 
were extracted and stored at—25  °C. For each patient 
and for each blood sampling the presence of IgG against 
six Tat variants was tested on six sera dilutions (1/3, 1/9, 
1/27, 1/81, 1/243, 1/729, 1/2181, 1/6561). The ELISA tests 
were made in 2 days and the first day the six Tat variants 
were coated on 96 wheels NUNC plates in duplicate. We 
had six sera from each patient at M0, M2, M5, M7, M9 
& M12 and one plate per serum was used. The second 
day, the six sera of a same volunteer were added with 
the same dilutions (one sera for one plate) and the asso-
ciation Tat variants/Human IgG in the six dilutions was 
revealed with peroxide conjugate Goat anti Human IgG 
and the colorimetric ABTS reaction at 433  nm, meas-
ured with a BIOTEK spectrophotometer. The six plates 
were measured the same day with a delay of 45 min cor-
responding to the time of incubation for each plate with 
ABTS. The intra assay variability of the ELISA test was 
monitored at the end of the second day with OD values 
that had to have a standard deviation <0.2 OD between a 
same Tat variant and a same dilution in the duplicate of 
a same plate. Inter assay variability was monitored with 
ELISA test that had to be reproducible at least twice for 
each volunteer with a delay of 6  months between two 
experiments. After vaccination, a specific response due 
to the vaccine was characterized by the apparition of an 
immune response against Tat variants for volunteers who 
had no response before vaccination. For volunteers who 
had an immune response against Tat before vaccination, 
a specific response due to the vaccine was characterized 
by recognition at a lower dilution of the same Tat variant 
and/or recognition of new Tat variants.
Randomization and masking
It was a mono centric clinical study and it was double-
blind with respect to vaccine dose assignment. The injec-
tions occurred in the “Centre d’Investigation Clinique” 
(CIC) in the UCH “la Conception”. The volunteers and the 
investigators in the CIC were unaware of the content in 
the syringes. Pharmacists, from the “Pharmacie à Usage 
Interne” (PUI) in the UCH “la Conception”, prepared 
and distributed the syringe the morning of the arrival of 
each volunteer in the CIC according to a schedule pre-
viously planned with the volunteer and in agreement 
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with the EVATAT protocol. Volunteers (n  =  48) were 
randomly assigned (1:1:1:1) to receive either 0, 11, 33 or 
99 µg of a synthetic Tat Oyi complemented with a saline 
buffer. Randomization was carried with volunteers strati-
fied in four block size named A, B, C and D and the vac-
cine doses corresponding to each letter was not known. 
The randomization scheme was prepared by Dr. Albert 
Darque in the PUI and securely stored with restricted 
access. No request to unmask study participants was 
asked for EVATAT study and the randomization was 
unmasked only on September 15th, 2015 after the “freez-
ing” of EVATAT data from all investigators.
Statistical analysis
The sample sizes have not been evaluated with a statisti-
cal methodology including power analysis. Nonparamet-
ric testing procedures were planned, and multifactorial 
analysis of RNA, DNA, CD4, CD8 was the core of the 
study. It was not possible to use standard tools to deter-
mine sample sizes according to a pre-specified power of 
the analysis (that requires a given value for the detectable 
difference). A total amount of 48 participants divided in 
four groups was accepted by authorities for a phase I/
IIa clinical trial, and ensured enough sample sizes for an 
exploratory statistical analysis. Volunteers with undetect-
able HIV RNA (<40 copies/mL) or HIV DNA (<20 cop-
ies/106 PBMC) were counted according to the “worst 
case scenario”, which were 39 copies for HIV RNA and 19 
copies for HIV DNA (respectively 1.6 log and 1.3 log. The 
non parametric Mann and Whitney test [36] was used as 
a standard test. All p values are one-sided because of an a 
priori knowledge of the expected variation between pla-
cebo and vaccine groups. To compare vaccinated groups 
with a placebo require multiple comparisons that may 
induce type I family wise errors when non adjusted p 
values are used to detect significant differences between 
groups [37–39]. This is especially the case for large num-
ber of groups and unforeseen comparisons. Our analy-
ses do not suffer from this problem because only three 
groups are compared to the placebo. Moreover, these 
comparisons were planned in the statistical analysis plan 
of the study and have not to be considered as unplanned 
subgroup comparisons. Thus, despite the fact that the 
sample sizes was most of the time not sufficient enough 
to ensure a statistical significance of the observed differ-
ences by adjusting for multiples comparisons, we pro-
vided non adjusted p values for one-sided Mann and 
Whitney tests as elements for discussion. An overall 
Kruskal–Wallis test would not have revealed a statisti-
cally significant difference among groups, mainly due to 
a lack of power in comparison of one control group ver-
sus the three other groups with 48 patients. The Consort 
2010 [40] warns against the risk of spurious findings, that 
is why these statistical data must be seen as an explora-
tory analysis.
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